Table 1.
Clinical characteristics of participants.
| Characteristics | N = 59 (peripheral vein) | N = 15 (three source) |
|
| ||
| Male (n, %) | 26 (44.1%) | 8 (53.3%) |
| Age (yrs) | 73.3 ± 5.5 | 74.1 ± 4.9 |
| STS (%) | 8.04 ± 4.6 | 9.0 ± 3.4 |
| NYHA III/IV | 55 (93.2%) | 14 (93.3%) |
| Body mass index (kg/m2) | 22.4 ± 3.3 | 22.9 ± 4.1 |
| Hypertension (n, %) | 24 (40.7%) | 12 (80.0%) |
| Diabetes (n, %) | 5 (8.5%) | 1(6.7%) |
| Chronic obstructive pulmonary disease (n, %) | 25 (42.4%) | 10 (66.7%) |
| Coronary artery disease (n, %) | 26 (44.1%) | 5 (33.3%) |
| Peripheral artery disease (n, %) | 40 (67.8%) | 8 (53.3%) |
| Cerebrovascular disease (n, %) | 11 (18.6%) | 3 (20%) |
| Chronic kidney disease (n, %) | 11 (18.6%) | 3 (20%) |
| Maximum transaortic velocity (m/s) | 5.0 ± 0.8 | 4.9 ± 0.7 |
| Mean transaortic gradient (mmHg) | 62.9 ± 20.6 | 64.1 ± 17.1 |
| Left ventricular ejection fraction (%) | 50.7 ± 15.2 | 48.1 ± 13.2 |
| Left ventricular mass (g) | 296.0 ± 97.6 | 310.8 ± 78.8 |
| Left ventricular mass index (g/m2) | 177.0 ± 56.7 | 183.6 ± 43.6 |
| Preprocedure NT-ProBNP (pg/ml) | 3665.0 (1056–12209.3) | 2572.0 (1999.0–8357.0) |
| 30-day mortality | 1 (1.7%) | 1 (6.7%) |
| 1-year mortality | 3 (5.1%) | 3 (20%) |
NYHA, New York Heart Association.